Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Top Cited Papers
- 29 July 2016
- journal article
- research article
- Published by Elsevier in The Lancet Oncology
- Vol. 17 (9), 1248-1260
- https://doi.org/10.1016/s1470-2045(16)30122-x
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanomaCancer, 2013
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Distinct Sets of Genetic Alterations in MelanomaNew England Journal of Medicine, 2005
- Mutations of the BRAF gene in human cancerNature, 2002
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993